A detailed history of Roof Eidam & Maycock transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Roof Eidam & Maycock holds 5,600 shares of BMY stock, worth $301,056. This represents 0.06% of its overall portfolio holdings.

Number of Shares
5,600
Previous 5,600 -0.0%
Holding current value
$301,056
Previous $303,000 23.43%
% of portfolio
0.06%
Previous 0.08%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 07, 2024

SELL
$48.48 - $57.85 $189,072 - $225,615
-3,900 Reduced 41.05%
5,600 $287,000
Q3 2023

Oct 19, 2023

BUY
$57.89 - $64.73 $69,468 - $77,676
1,200 Added 14.46%
9,500 $551,000
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $54,784 - $64,872
-800 Reduced 8.79%
8,300 $597,000
Q2 2022

Aug 05, 2022

SELL
$72.62 - $79.98 $27,813 - $30,632
-383 Reduced 4.04%
9,100 $701,000
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $120,667 - $140,670
-2,250 Reduced 19.18%
9,483 $591,000
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $17,056 - $18,901
-297 Reduced 2.47%
11,733 $707,000
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $10,635 - $12,433
194 Added 1.64%
12,030 $707,000
Q4 2019

Jan 17, 2020

BUY
$49.21 - $64.19 $9,842 - $12,838
200 Added 1.72%
11,836 $760,000
Q1 2019

May 10, 2019

BUY
$45.12 - $53.8 $232,368 - $277,070
5,150 Added 79.4%
11,636 $555,000
Q2 2018

Aug 07, 2018

SELL
$50.53 - $62.98 $14,451 - $18,012
-286 Reduced 4.22%
6,486 $359,000
Q1 2018

May 11, 2018

BUY
$59.92 - $68.98 $17,137 - $19,728
286 Added 4.41%
6,772 $428,000
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $358,221 - $413,417
6,486
6,486 $413,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $114B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Roof Eidam & Maycock Portfolio

Follow Roof Eidam & Maycock and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Roof Eidam & Maycock, based on Form 13F filings with the SEC.

News

Stay updated on Roof Eidam & Maycock with notifications on news.